ABL2 Y399C

CI-VAR-00004809Explore in graph →CIViC 3689

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
ABL2 Y399C	Dasatinib + ImatinibSubstitutes	Predictive	D	Does Not Support Sensitivity Response	3	rejected	EID10078 Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.